Voltar
Artigo Acesso aberto Revisado por pares
BIBTEX RIS

Effect of Hyperthermic Intraperitoneal Chemotherapy on Cytoreductive Surgery in Gastric Cancer With Synchronous Peritoneal Metastases: The Phase III GASTRIPEC-I Trial

2023; Lippincott Williams & Wilkins; Volume: 42; Issue: 2 Linguagem: Inglês

10.1200/jco.22.02867

ISSN

1527-7755

Autores

Beate Rau, Hauke Lang, Alfred Koenigsrainer, Ines Gockel, Horst-Guenter Rau, Hendrik Seeliger, C. Lerchenmueller, Daniel Reim, Roger Wahba, Martin K. Angele, Steffen Heeg, Tobias Keck, Arved Weimann, Stefan A. Topp, Pompiliu Piso, Andreas Brandl, Silke Schuele, Peter Jo, Johann Pratschke, Sandra Wegel, Alexander Rehders, Nicolas Moosmann, Jochen Gaedcke, Volker Heinemann, Evelyn Trips, Markus Loeffler, Peter M. Schlag, Peter Thuss‐Patience,

Tópico(s)

Ovarian cancer diagnosis and treatment

Resumo

In patients with peritoneal metastasis (PM) from gastric cancer (GC), chemotherapy is the treatment of choice. Cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) are still being debated. This randomized, controlled, open-label, multicenter phase III trial (EudraCT 2006-006088-22; ClinicalTrials.gov identifier: NCT02158988) explored the impact on overall survival (OS) of HIPEC after CRS.

Referência(s)